Back to blog
Echelon Biosciences Inc. is pleased to join the NIH Glycoscience Common Fund Program listing of Companies w/ Glycoscience Catalogs. Echelon is committed to providing a wide range of tools supporting hyaluronic acid and glycosaminoglycan research and is pleased for the opportunity to bring these tools to established and new researchers alike in support of this important NIH initiative.
About the NIH Common Fund
The NIH Common Fund programs address emerging scientific opportunities and pressing challenges in biomedical research that no single NIH Institute or Center (IC) can address on its own, but are of high priority for the NIH as a whole. The Common Fund is a unique resource at NIH where high-risk, innovative endeavors with the potential for extraordinary impact can be supported. Common Fund programs are short-term, goal-driven strategic investments, with deliverables intended to develop innovative tools and technologies and catalyze research across multiple biomedical research disciplines.
About the Glycoscience Program
The goal of the Common Fund’s Glycoscience program is to create new resources, tools, and methods to make the study of glycans (sugars) more accessible to the broader research community. Glycans play a critical role in nearly all aspects of biology, ranging from how our bodies recognize and fight viruses and bacteria to how proteins are moved throughout our cells to perform different tasks. Despite their importance, the study of glycans has been limited due to the complexity surrounding the chemistry to make, study, and sequence all the different glycans in our body. In an effort to combat this, the Glycoscience program has developed a variety of tools, resources, and information for researchers unfamiliar with glycans to incorporate them into their studies. Echelon is proud to offer our broad range of tools for Glycosaminoglycan Research in support of this crucial research effort.
NOTE: NIH does not endorse or recommend any commercial products, processes, or services.
0.2
/ 0.3
Related Articles
Stay informed with our informative blog posts.
VION Biosciences Acquires Industry Leader in Specialty Lipids and Lipid Nanoparticles, Echelon Biosciences
Acquisition serves as second for VION as it expands platform offering and product line, moves closer to supporting drug manufactur
Echelon joins NIH Common Fund Resources List
Echelon Biosciences Inc. is pleased to join the NIH Glycoscience Common Fund Program listing of Companies w/ Glycoscience Catalogs
Echelon Biosciences participates at Life Sciences Day with BioUtah
Utah’s flourishing Life Sciences Industry was proudly on display at the 2023 Annual Life Sciences Day on Capitol Hill. Echelon B
Echelon Biosciences announces partnership with ProBioscience Technologies for distribution in Southeast Asia
Echelon Biosciences Inc. (EBI) is excited to announce a new partnership with ProBioscience Technologies for product distribution i
Echelon Biosciences selected as the 2022 Bioz “Rising Star” ELISA Winner
November, 15, 2022 – Salt Lake City, UT, USA – Echelon Biosciences announces that it has been selected as the 2022 Bioz S
25 Years of Supporting Science
This year marks a major milestone for Echelon Biosciences (EBI). We are celebrating our 25th Anniversary as a company. EBI’s
0.3
/ 0.3
Get in Touch
If you have any questions or would like to learn more about our services, feel free to reach out to us. We’re here to help!
Biosciences